Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
about
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implicationsResveratrol Co-Treatment Attenuates the Effects of HIV Protease Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial Respiration.Proliferative and non-proliferative lesions of the rat and mouse soft tissue, skeletal muscle and mesothelium.Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 miceHIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studyLopinavir/Ritonavir Impairs Physical Strength in Association with Reduced Igf1 Expression in Skeletal Muscle of Older Mice.Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathwaysTargeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential.Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles.Lopinavir impairs protein synthesis and induces eEF2 phosphorylation via the activation of AMP-activated protein kinase.Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.Mouse Models of Lipodystrophy Key reagents for the understanding of the metabolic syndrome.Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era.Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.Evaluation of Oral Antiretroviral Drugs in Mice With Metabolic and Neurologic Complications
P2860
Q24598812-66767E3C-BF49-451A-8BC9-E9122E1D2F3CQ30397743-5CC47692-325F-49D4-8C52-FD82A1CF4D6BQ33880079-53820A59-5425-4E10-A01C-1AECAFEEFE66Q34349192-BF27E502-1DA5-4261-94E5-1D0238B1AD54Q34534986-30C289B6-0606-4B87-A95D-4F01D9E2C824Q35915493-0DF3CD3F-3594-4FE5-9298-C9E06048906AQ36104280-9D60DDF7-09DA-48DD-B3DA-1C92E1BA4CABQ37033675-1C522955-E472-4443-983B-0620F44FFBCBQ37061986-97DEBF24-B6A9-418E-A3CF-4306C9B061A0Q38764703-7104E25D-BF3D-45CD-AA65-522C25627DBCQ41920342-1739D5D7-FF02-40E6-BE72-DF6BFBCE5AD6Q42176233-E4272A45-37E6-461A-A8FE-6B725E11B011Q42945651-F14408D7-5AE4-4D26-87AD-046BED66AC59Q47112253-A4A4375A-C737-4CA2-A6DD-983AD47FDDDDQ50054188-43B5AEFE-36A5-4A54-BA68-45C5B8EF2103Q58764782-CA43D2E9-61AD-4482-851E-19484AACC492
P2860
Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Long-term treatment with lopin ...... pheral adipose depots in mice.
@en
type
label
Long-term treatment with lopin ...... pheral adipose depots in mice.
@en
prefLabel
Long-term treatment with lopin ...... pheral adipose depots in mice.
@en
P2093
P2860
P356
P1476
Long-term treatment with lopin ...... pheral adipose depots in mice.
@en
P2093
Bernard Binétruy
Christophe Perrin
Jacques Durant
Laurence Heripret
Matthieu Prot
Myriam Aouadi
Nathalie Cardot-Leccia
Pierre Dellamonica
Rodolphe Garraffo
Thibaud Lavrut
P2860
P304
P356
10.1128/AAC.00625-06
P407
P577
2006-09-25T00:00:00Z